Transitioning Your Biologic to an Auto-Injector

As your product’s presentation progresses into an auto-injector within the clinic, initial launch, or follow-on markets, it’s critical your manufacturing and packaging partner understands:

‌

Planning a commercial launch of a biologic into the market is key to its success. In certain instances, there may be a need to get to market much faster than the typical approach. With an experienced development and manufacturing partner, sponsor companies could take their biologic to market within just 30-45 days following regulatory approval.

‌

In this webinar, AstraZeneca and Catalent Biologics discussed a case study on a 30-day commercial launch plan for a product into new markets and why this approach was important for patients.

Technology transfer is a challenging and multi-faceted endeavor, with multiple variables that must be carefully considered. In this article, get insights on key considerations for a successful process transfer for manufacturing a drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.